Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I will have this one on my watch list!! It did a huge climb since spring!
Good info.. Nice history lesson... lol
bio crushed is correct!
$ISIS DD Notes ~ http://www.ddnotesmaker.com/ISIS
bullish very long term
$ISIS recent news/filings
## source: finance.yahoo.com
Wed, 29 Oct 2014 00:10:00 GMT ~ Regulus Announces Pricing of Public Offering of Common Stock
[PR Newswire] - Regulus will not receive any proceeds from the sale of the shares of common stock by Isis. Regulus anticipates using the net proceeds from the offering to fund preclinical and clinical development of its clinical candidates, RG-101 and RG-012, and its other initial microRNA development candidates, for the identification and validation of additional microRNA targets, and for capital expenditures, working capital and general corporate purposes. Deutsche Bank Securities and BMO Capital Markets are acting as joint book-running managers for the offering. Needham & Company, Wedbush PacGrow Life Sciences and FBR are acting as co-managers.
read full: http://finance.yahoo.com/news/regulus-announces-pricing-public-offering-001000158.html
*********************************************************
Tue, 28 Oct 2014 23:24:10 GMT ~ Lightning Round: GNC, Goldman and more
read full: http://www.cnbc.com/id/102128707?__source=yahoo%7cfinance%7cheadline%7cheadline%7cstory&par=yahoo&doc=102128707
*********************************************************
Tue, 28 Oct 2014 23:00:00 GMT ~ Cramer: Time for this CEO to hit the road
read full: http://finance.yahoo.com/video/cramer-time-ceo-hit-road-230000748.html
*********************************************************
Fri, 17 Oct 2014 01:35:45 GMT ~ World Leading Clinical Expert to Present to Shareholders
[at noodls] - _ December 2008 9 October 2014 World Leading Clinical Expert Professor Peter Trainer to Present to Shareholders on Successful ATL1103 Phase II Trial Results Antisense Therapeutics Ltd (ASX:ANP or "the ...
read full: http://www.noodls.com/view/CD2300492046816E50F45395796490A01F74AD75
*********************************************************
Mon, 13 Oct 2014 20:50:28 GMT ~ Isis Pharmaceuticals Unveils Mid-Stage Data on ISIS-SMNRx
read full: http://finance.yahoo.com/news/isis-pharmaceuticals-unveils-mid-stage-205028724.html
*********************************************************
$ISIS charts
basic chart ## source: stockcharts.com
basic chart ## source: stockscores.com
big daily chart ## source: stockcharts.com
big weekly chart ## source: stockcharts.com
$ISIS company information
## source: otcmarkets.com
Link: http://www.otcmarkets.com/stock/ISIS/company-info
Ticker: $ISIS
OTC Market Place: Not Available
CIK code: 0000874015
Company name: Isis Pharmaceuticals, Inc.
Company website: http://www.isip.com
Incorporated In: DE, USA
$ISIS share structure
## source: otcmarkets.com
Market Value: $5,466,452,765 a/o Oct 28, 2014
Shares Outstanding: 117,735,360 a/o Aug 01, 2014
Float: Not Available
Authorized Shares: Not Available
Par Value: 0.001
$ISIS extra dd links
Company name: Isis Pharmaceuticals, Inc.
Company website: http://www.isip.com
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/ISIS/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/ISIS/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=ISIS+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=ISIS+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=ISIS+Industry
## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/ISIS/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/ISIS/news - http://finance.yahoo.com/q/h?s=ISIS+Headlines
## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/ISIS/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/ISIS/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/ISIS/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/ISIS/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/ISIS/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/ISIS/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/ISIS/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/ISIS/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=ISIS+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/ISIS
DTCC (dtcc.com): http://search2.dtcc.com/?q=Isis+Pharmaceuticals%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Isis+Pharmaceuticals%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Isis+Pharmaceuticals%2C+Inc.&x=0&y=0
WHOIS (domaintools.com): http://whois.domaintools.com/http://www.isip.com
Alexa (alexa.com): http://www.alexa.com/siteinfo/http://www.isip.com#
Corporate website internet archive (archive.org): http://web.archive.org/web/*/http://www.isip.com
## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/ISIS/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/ISIS
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/ISIS/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/ISIS/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/ISIS/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000874015&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/ISIS/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/ISIS/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/ISIS/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/ISIS/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=ISIS&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=ISIS
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/ISIS/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=ISIS+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=ISIS+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=ISIS
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=ISIS
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=ISIS+Cash+Flow&annual
## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/ISIS/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=ISIS+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/ISIS.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=ISIS
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/ISIS/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/ISIS/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/ISIS/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/ISIS/insider-transactions
## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/ISIS
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/ISIS
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/ISIS:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=ISIS
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=ISIS
$ISIS DD Notes ~ http://www.ddnotesmaker.com/ISIS
$ISIS Cowen Reiterates Outperform On Isis Pharmaceuticals Following Clinical Update http://www.smarteranalyst.com/2014/10/10/cowen-reiterates-outperform-isis-pharmaceuticals-following-clinical-update/
And 24 hrs later I sell the 500 shares I bought on yesterday's dip in the 38s at 41.70 this morning. Nice tidy little profit in 24 hrs.
Sure... But this is a traders dream in days like this. Look how many times in the last month alone it's fallen 5-10% in a day or two only to come right back to even ++
I buy this on every dip I see. Bought another 500 when it fell back below 40. Those will get sold in the next week or two at 42+. Rinse , repeat.
My only response...
LOL!!!
I don't think the Cramer pump before the biotech dump on Monday was a coincidence.
I don't believe anything that he or his associates say (Feuerstein) is anything less than self (aka Market) serving.
Why are people such SUCKERS for media types?
Again I agree, they are worried about the sector recovering from the early summer hit. HALO was down on drug approval.
I agree - IMO it was MM's covering short from 60...
Pharma / bio also just getting crushed across the board today. Perhaps that's due for this sector. Just seems sudden
Biib, gild, CELG, acor, etc. all down big this AM
Think its a risky short play with the buyout speculation. Even if its a slim chance... You could get crushed short if that news dropped.
Like the company. Will buy more on days like this. No reason it should stay down fundamentally in my opinion.
Wtf is going in with this company this AM?
Cramer loves this company. Must be in his charity trust fund.
Should be an interesting day -
Cramer pump
http://www.cnbc.com/id/101993382
I totally believe in the company, but that doesn't mean that Cramer isn't helping to orchestrate an orderly recovery from the spring sell off.
I have looked at their released data for their SMA study. It looks very promising. I am guessing that they found the right oligo for that disease. That alone will be huge. The other projects I do not know...
Only buyout speculation? I would like to see an announcement of a partnering deal for Factor XI, glucagon receptor, or maybe European partnership for APOCIII. All this rumor mongering about a takeover makes me more nervous than excited, and I'd prefer to have some news of substantial revenue from deals that seem ready to make if not overdue.
As rumors swirl thar there will be a takover, this stock is soaring. If isis gets bought out hold onto your shares... Pps could gi through the roof!!
Hello ISIS looks like its popping pretty good...
http://stockcharts.com/c-sc/sc?s=ISIS&p=D&yr=1&mn=0&dy=0&i=p62644462939&r=9553
Price target is 52.00, get'em while you can!
I have a really good feeling about the phase 3 clinical trials that are underway. This stock is performing beautifully!
Huge upside in process. Jim Cramer loves this stock.
Bombs are dropping on ISIS today!
We Expect ISIS Shares To Outperform The Market, Says Cowen http://www.smarteranalyst.com/2014/08/05/we-expect-isis-shares-to-outperform-the-market-says-cowen/
PhaseII clinical trials are underway. Exciting times for this company!
Amazing trading day.... Regained the losses from last week
The drug has been shown to be safe at several times the therapeutic dosage in humans. Very good news for ISIS.
What would a take over mean for pps?
Insiders doing the "Hustle" it seems.
Another positive sign for the med science-impaired investor.
OK - I admit to having a limited understanding of the science, but I have a more intimate than I would wish acquaintance with the manipulations of the market. So while I believe biotech is an important scientific area, the charts are my guide and based on that I am heavily committed to ISIS.
Would anyone care to illuminate and discuss the following? It seems to be comprehensive and rational.
This helps too:
Isis Pharmaceuticals reports final Phase 2 data on ISIS-GCGR Rx
Isis Pharmaceuticals reports final Phase 2 data on ISIS-GCGR Rx
Isis Pharmaceuticals announced the final results from its Phase 2 study of ISIS-GCGRRx in patients with type 2 diabetes uncontrolled on stable metformin therapy. In this study, patients in the per protocol population treated with ISIS-GCGRRx in addition to metformin achieved absolute mean reduction in hemoglobin A1c of up to 2.25 percentage points from baseline after only 13 weeks of treatment. Patients receiving placebo had an 0.25 percentage point reduction in HbA1c. In this study, more than half of the PP patients achieved an HbA1c level of less than or equal to 7.0 percent. PP patients treated with ISIS-GCGRRx in this study also achieved a mean reduction of up to 74.9 µmol/L in fructosamine. In addition, in these patients a mean increase in total GLP-1 of up to 19.97 pmol/L was observed.
Yeah, it's carry over as Guy Adami made ISIS his "Final Trade" BUY on Friday not as a stock pick but as a potential takeover candidate. Lots of chatter about ISIS being bought out i.e., Cramer the week before mentioned it too...
ISIS will be taken over...possibly this summer.
CARLSBAD, Calif., June 10, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that AstraZeneca has initiated a Phase 1 clinical study of ISIS-ARRx in patients with cancer. Isis earned a $15 million milestone payment associated with the clinical advancement of ISIS-ARRx. ISIS-ARRx is an antisense drug designed to treat patients with prostate cancer by inhibiting the production of the androgen receptor (AR). AstraZeneca is planning to develop ISIS-ARRx broadly to treat patients under a variety of settings during the course of prostate cancer treatment, including both as a single agent and in combination therapy.
Insiders excersize options and sell small amount to pay employment tax and set cap gain level prior to major news.
Will this data be outstanding?
Jim Cramer mention ISIS as "Buy" at the top of "Mad Money" show today!
Antisense therapy for hepatitis C virus infection -Commentary
Download the PDF here
http://www.natap.org/2013/HCV/011314_07.htm
Journal of Hepatology January 2014
Ype P. de Jong1,2, Ira M. Jacobson1,
1Division of Gastroenterology and Hepatology, Center for the Study of Hepatitis C, Weill Cornell Medical College, New York, NY, USA; 2Laboratory of Virology and Infectious Disease, Center for the Study of Hepatitis C, The Rockefeller University, New York, NY, USA
COMMENTARY ON:
Treatment of HCV infection by targeting microRNA. Janssen HL, Reesink HW, Lawitz EJ, Zeuzem S, Rodriguez-Torres M, Patel K, van der Meer AJ, Patick AK, Chen A, Zhou Y, Persson R, King BD, Kauppinen S, Levin AA, Hodges MR. N Engl J Med. 2013 May 2;368(18):1685-94. doi: 10.1056/NEJMoa1209026. Copyright 2013. Abstract reprinted by permission from the Massachusetts Medical Society.......http://www.ncbi.nlm.nih.gov/pubmed/23534542
NEJM- Treatment of HCV Infection by Targeting
MicroRNA......http://www.natap.org/2013/HCV/033013_04.htm
3 commentaries/ background on microRNA Miravirsen.
(1) Current and Future Therapies for Hepatitis C Virus Infection, T. Jake Liang, M.D., and Marc G. Ghany, M.D., M.H.Sc., N Engl J Med 2013; 368:1907-1917May 16, 2013DOI: 10.1056/NEJMra1213651
(2) Editorial, Micromanaging Hepatitis C Virus, Judy Lieberman, M.D., Ph.D., and Peter Sarnow, Ph.D., N Engl J Med 2013; 368:1741-1743May 2, 2013DOI: 10.1056/NEJMe1301348
(3) Correspondence, HCV Infection and Miravirsen, N Engl J Med 2013; 369:877-878August 29, 2013DOI: 10.1056/NEJMc1307787
Abstract. Background: The stability and propagation of hepatitis C virus (HCV) is dependent on a functional interaction between the HCV genome and liver-expressed microRNA-122 (miR-122). Miravirsen is a locked nucleic acid-modified DNA phosphorothioate antisense oligonucleotide that sequesters mature miR-122 in a highly stable heteroduplex, thereby inhibiting its function. Methods: In this phase 2a study at seven international sites, we evaluated the safety and efficacy of miravirsen in 36 patients with chronic HCV genotype 1 infection. The patients were randomly assigned to receive five weekly subcutaneous injections of miravirsen at doses of 3 mg, 5 mg, or 7 mg per kilogram of body weight or placebo over a 29-day period. They were followed until 18 weeks after randomization.
Results: Miravirsen resulted in a dose-dependent reduction in HCV RNA levels that endured beyond the end of active therapy. In the miravirsen groups, the mean maximum reduction in HCV RNA level (log10 IU per milliliter) from baseline was 1.2 (P = 0.01) for patients receiving 3 mg per kilogram, 2.9 (P = 0.003) for those receiving 5 mg per kilogram, and 3.0 (P = 0.002) for those receiving 7 mg per kilogram, as compared with a reduction of 0.4 in the placebo group. During 14 weeks of follow-up after treatment, HCV RNA was not detected in one patient in the 5-mg group and in four patients in the 7-mg group. We observed no dose-limiting adverse events and no escape mutations in the miR-122 binding sites of the HCV genome.
Conclusions: The use of miravirsen in patients with chronic HCV genotype 1 infection showed prolonged dose-dependent reductions in HCV RNA levels without evidence of viral resistance. (Funded by Santaris Pharma; ClinicalTrials.gov number, NCT01200420.)
MicroRNAs are small non-coding RNAs encoded by the human genome that transcriptionally and post-transcriptionally modify gene expression. The microRNA-122 (miR-122) forms the dominant microRNA in the liver and is exclusively expressed in hepatocytes. It has been implicated in multiple different processes, including lipid metabolism, cell differentiation, iron metabolism and hepatic circadian regulation [1]. In 2005 Jopling and colleagues identified miR-122 as an essential co-factor for hepatitis C virus (HCV) replication [2]. The 5' untranslated region (UTR) of HCV is highly conserved across genotypes and contains two miR-122 binding sites, disruption of which blocks HCV replication through unknown mechanisms [3]. Miravirsen, a 15 nucleotide long oligonucleotide complementary to miR-122, can form stable heteroduplexes with miR-122 and interfere with HCV replication. Whether miravirsen exerts its antiviral effects predominantly through sequestration of available miR-122, indirectly through disrupting lipid pathways essential to the viral lifecycle, or through other mechanisms remains under active investigation. Its efficacy against chronic HCV infection was first shown in studies in chimpanzees, the only natural HCV animal model. Chimpanzees that received the highest, 5 mg/kg, dose through a weekly infusion had a marked decrease in plasma and liver HCV RNA [4], which led to clinical testing of miravirsen. Now Janssen and colleagues report on their findings from a phase 2a study in treatment naive non-cirrhotic patients chronically infected with HCV genotype 1 [5]. They enrolled 36 patients who were randomized to 5 weekly subcutaneous injections with three different doses of miravirsen (3, 5 or 7 mg/kg) or placebo, with the possibility of pegylated interferon (PegIFN) and ribavirin (RBV) rescue at defined time points after miravirsen completion and at the investigator's discretion. After the last injection of miravirsen, patients were followed for an additional 14 weeks for viral kinetics and adverse events. They found that HCV RNA showed a dose-dependent decline, with 1 (11%) patient in the 5 mg/kg and 4 (44%) patients in the 7 mg/kg groups reaching undetectable HCV RNA levels, all after the fifth dose of miravirsen. Notably, the individual response curves shown by the authors were quite variable, even with the highest dose. Three of the patients whose HCV RNA became undetectable relapsed 4-5 weeks later and one patient went on to be treated with PegIFN/RBV. The long term outcome in the remaining patient who achieved an undetectable HCV RNA at study week 14 and remained undetectable through week 18 was not reported. Adverse events were generally mild with only injection site reactions being likely related to miravirsen administration.
Treatment for chronic HCV, which until recently was plagued by poor tolerability and suboptimal response rates, is undergoing a profound paradigm shift with the development of HCV protease, polymerase and NS5A inhibitors and the demonstration of extremely high rates of sustained virologic response with interferon-free combination regimens. Although DAAs currently under clinical investigation generally have high potency, all but nucleotide polymerase inhibitors have low barriers to resistance and therefore combination therapy appears necessary for most HCV genotypes. In contrast to the rapid decline in HCV RNA level within days after starting potent DAAs, there was a <2 log decline at week 4 even with the highest dose of miravirsen. Given our lack of understanding how HCV utilizes miR-122 in its life cycle [6] and by what mechanisms miravirsen blocks HCV replication, it is difficult to account for the different kinetics. Apart from being amongst the first successful antisense oligonucleotide therapies in man, the current study by Janssen and colleagues is notable for additional reasons. First, the strategy of targeting miR122 is distinct from that underlying the three major DAA classes under investigation; in theory, it can be used complementary to DAAs. Similar to strategies that interfere with cyclophilin A [7], miravirsen is an example of the capacity for an inhibitor of a host factor essential for the HCV life cycle to abrogate viremia with no evidence of viral escape. Although theoretical escape mutants can be engineered in vitro [8], the high barrier to resistance and the duration of post-treatment viral suppression in some patients (to the end of study in one patient), imply the possibility that miravirsen could lead to viral eradication with a monotherapy. To address this ambitious proposition, the authors mention that longer duration studies with 12 weeks of miravirsen monotherapy are ongoing. Finally, given the highly conserved 5' UTR and miravirsen's ability to block replication of all HCV genotypes in vitro [8], it is likely that the current results with genotype 1 patients will hold true across genotypes. This may make therapy with miravirsen a potential approach for genotypes that may be less susceptible to some of the DAAs in development.
Its attractive features and favorable short-term safety profile notwithstanding, antisense therapy warrants a note of caution. MiR-122 modulates the expression of an estimated 200 hepatocyte proteins, some of which have been implicated in cholesterol metabolism and cancer development. Although not confirmed in the setting of HCV infection, low miR-122 levels expressed in hepatocellular carcinomas (HCCs) appear to predict a poor prognosis [9], as acknowledged by the authors, and decrease susceptibility to sorafenib in cell culture[10]. Furthermore germline deletion of miR-122 was recently shown to lead to steatohepatitis and spontaneous HCC development in mice [11], [12]. The lower serum cholesterol levels observed in patients after miravirsen administration [5] illustrate that other miR-122 targets are also affected during therapy. In a population at increased risk for developing HCC, these experimental findings warrant careful scrutiny during further clinical development.
The potential benefits of miravirsen must be weighed in the context of the very high rates of sustained virologic response in recent studies of oral DAA combination regimens. The requirement for parenteral administration is a potential drawback, but this may be mitigated if the authors prove to be correct in their suggestion that the pharmacokinetic profile of the drug makes once monthly dosing feasible. Overall, the results of Janssen et al. represent an intriguing proof of concept for a new class of host factor antagonists that combine antiviral potency with a high barrier to resistance. The formulation of a developmental pathway for miravirsen may prove to be challenging in the current environment, but it deserves further study and could have a therapeutic role, particularly if DAA combinations leave unmet needs in some patient populations.
... agreed these guys are hacking the healthcare industry ...
Isis is about to go big
Followers
|
47
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
488
|
Created
|
02/21/06
|
Type
|
Free
|
Moderators |
Ionis Pharmaceuticals, Inc., through its drug discovery platform based on antisense technology, discovers and develops drugs that bind to RNA antisense technology. The company has commercialized its antisense drug and has 19 drugs in development. Ionis' drug development programs are focused on treating cardiovascular, metabolic, and severe neurodegenerative diseases and cancer. It licenses its drugs to partners prior to late-phase development and commercialization. The company and Alnylam Pharmaceuticals jointly own Regulus Therapeutics Inc., a company focused on the discovery, development, and commercialization of microRNA therapeutics. Ionis is the owner or exclusive licensee of approximately 1,600 issued patents worldwide. The company was founded in 1989 and is based in Carlsbad, California.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |